Saturday 17 October 2026 Export ARDX’s income statement to Excel — free account

Ardelyx, Inc.

Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024. In the quarter to June 2026, revenue grew 23.8%, EPS grew 12.5%, free cash flow grew 75.3% and total debt rose 25.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

3.09 0.18 −5.50%

Follow ARDX

Alert me

Market cap: $814.9M
P/E: 0.0×
Fwd P/E: −122×
Dividend yield: —
F-score: 2/9
Altman Z: 1.12
Beneish M: −2.40
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.95

Total sells 4.30

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	1	—	—	—	—	—	—	—	—
Sell	6	—	1	9	1	1	9	2	1	8	—	—

Insider Ownership 3.48%

Capital & Financial Ratios $m

Market Cap 814.85

Revenue 450.89

Net Income (55.70)

Free Cash Flow (17.92)

Net Debt (30.01)

Current Ratio 3.34

Debt/Equity 1.69

P/E ratio 0.00

Fwd P/E (122.00)

P/S ratio 1.70

P/B ratio 5.14

Past 5Y EPS Growth —

This Y EPS Growth 29.55%

Next Y EPS Growth 238.33%

Next Y revenue growth 19.98%

Next 5Y EPS Growth 30.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.04%

10-year low 10-year high

P/B against its own 10 years 62.59%

10-year low 10-year high

EV/Sales against its own 10 years 2.87%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	184	250	265	282
Receivables	22	58	72	100
Inventory	12	21	18	26
Other	—	—	—	—
	246	356	382	442

	2023	2024	2025	Q'26
Payables	11	16	19	38
ST’ Debt	—	—	—	—
Other	15	35	48	71
	50	78	89	132

Compound Annual Growth %

	10y	5y	3y
Sales	29.12%	121.90%	98.40%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	4.37%	5.77%	19.30%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	94	121	—	—	—
’25	74	98	110	125	407
’24	46	73	98	116	334
’23	11	22	56	34	124
’22	0	3	5	44	52
’21	7	1	1	1	10
’20	1	2	3	2	8

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(32)	(6)	—	—	—
’25	(38)	(25)	0	21	(42)
’24	(36)	(19)	1	10	(45)
’23	(45)	(15)	(21)	(9)	(90)
’22	(28)	(31)	(25)	14	(70)
’21	(44)	(34)	(35)	(39)	(153)
’20	(25)	(19)	(20)	(18)	(81)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(32)	(6)	—	—	—
’25	(39)	(26)	0	21	(44)
’24	(36)	(20)	0	9	(46)
’23	(45)	(15)	(22)	(9)	(90)
’22	(27)	(31)	(25)	14	(68)
’21	(45)	(35)	(35)	(39)	(154)
’20	(25)	(19)	(20)	(18)	(82)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.15)	(0.07)	—	—	—
’25	(0.17)	(0.08)	0.00	0.00	(0.26)
’24	(0.11)	(0.07)	0.00	0.02	(0.17)
’23	(0.13)	(0.08)	0.03	(0.12)	(0.30)
’22	(0.21)	(0.19)	(0.14)	0.06	(0.42)
’21	(0.34)	(0.45)	(0.42)	(0.31)	(1.52)
’20	(0.25)	(0.28)	(0.20)	(0.32)	(1.05)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	6.36	4.05	1.60	1.70	4.22	0.82	0.49	2.63	4.32	3.21	Analyst estimates 2026–2028 Powerpack
	High	17.90	15.40	8.10	8.49	8.82	9.23	2.86	6.75	10.13	6.78
People
People	Employees	93	75	86	88	129	86	133	267	395	489
	Revenue/emp, $m	0.00	0.56	0.03	0.06	0.06	0.12	0.39	0.47	0.84	0.83
Income, $m
Income, $m	Revenue	—	42	3	5	8	10	52	124	334	407
	Gross margin, %	0.00	80.00	82.13	88.64	98.08	90.10	92.11	85.70	84.85	90.29
	EBT	(112)	(63)	(91)	(95)	(94)	(158)	(67)	(66)	(39)	(61)
	EBT margin, %	0.00	(150.38)	(3,501.88)	(1,792.03)	(1,245.69)	(1,566.42)	(128.84)	(52.65)	(11.65)	(14.89)
	Net income	(112)	(64)	(91)	(95)	(94)	(158)	(67)	(66)	(39)	(62)
	Depreciation	2	3	2	3	3	3	1	1	2	3
Per share, $
Per share, $	Revenue	0.00	0.89	0.05	0.08	0.08	0.10	0.33	0.57	1.42	1.69
	Earnings	(2.80)	(1.36)	(1.62)	(1.47)	(1.05)	(1.52)	(0.42)	(0.30)	(0.17)	(0.26)
	Cash flow	(2.31)	(1.37)	(1.25)	(1.19)	(0.91)	(1.46)	(0.44)	(0.41)	(0.19)	(0.18)
	Capex	(0.12)	(0.05)	(0.01)	0.00	0.00	(0.02)	0.01	0.00	0.00	(0.01)
	Free cash flow	(2.43)	(1.42)	(1.26)	(1.19)	(0.91)	(1.48)	(0.43)	(0.41)	(0.19)	(0.18)
	Book value	4.81	2.94	2.06	2.89	1.41	0.79	0.62	0.76	0.74	0.69
	Shares, m	40	47	56	64	90	104	159	219	235	241
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	10.94	38.60	90.24	76.55	11.35	8.15	10.66	3.57	3.45
	P/B	—	2.38	0.87	2.59	4.60	1.39	4.33	7.95	6.88	8.42
	EV/Sales	—	6.52	(7.00)	53.44	58.63	3.96	6.62	9.80	3.36	3.36
	EV/FCF	—	(2.93)	0.26	(3.73)	(5.43)	(0.26)	(5.05)	(13.54)	(24.45)	(31.16)
Cash, $m
Cash, $m	Operating cash flow	(93)	(65)	(70)	(76)	(81)	(153)	(70)	(90)	(45)	(42)
	Capex	(5)	(2)	0	0	0	(2)	2	0	(1)	(1)
	Free cash flow	(97)	(68)	(71)	(77)	(82)	(154)	(68)	(90)	(46)	(44)
Balance, $m
Balance, $m	Working capital	185	132	159	230	166	81	88	196	279	294
	Total debt	—	—	49	50	51	42	44	50	151	203
	Net debt	(201)	(134)	(119)	(197)	(136)	(75)	(80)	(134)	(99)	(62)
	Shareholders’ equity	193	139	116	187	126	83	98	167	173	167
Returns, %
Returns, %	ROA	(68.10)	(34.68)	(53.51)	(42.85)	(40.89)	(90.00)	(39.54)	(27.10)	(10.67)	(13.14)
	ROIC	0.00	(762.69)	0.00	0.00	0.00	(1,214.94)	(218.47)	(122.29)	(23.59)	(24.37)
	ROE	(74.42)	(38.70)	(71.57)	(62.78)	(60.31)	(151.55)	(74.28)	(49.83)	(23.01)	(36.21)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
KURA Kura Oncology, Inc.	$862.9M	— (loss-making)	— (loss-making)	+36.54% (above 0%: growing)	n/m	−109.05% (below 0%: shrinking)	98.84%	(349.77%)	Compare
ALMS Alumis Inc.	$842.4M	— (loss-making)	— (loss-making)	−37.66% (below 0%: shrinking)	n/m	+23.59% (above 0%: growing)	100.00%	(8,956.38%)	Compare
VSTM Verastem, Inc.	$835.9M	— (loss-making)	— (loss-making)	+1,775.43% (above 0%: growing)	n/m	−34.43% (below 0%: shrinking)	89.92%	(81.62%)	Compare
CRVS Corvus Pharmaceuticals, Inc.	$828.6M	— (loss-making)	—	—	n/m	−171.31% (below 0%: shrinking)	0.00%	0.00%	Compare
AVBP ArriVent BioPharma, Inc.	$827.9M	— (loss-making)	—	—	n/m	−51.51% (below 0%: shrinking)	—	0.00%	Compare
ARDX Ardelyx, Inc.	$814.9M	— (loss-making)	— (loss-making)	+23.77% (above 0%: growing)	n/m	+75.33% (above 0%: growing)	95.24%	(10.28%)
HELP Cybin Inc.	$807.3M	— (loss-making)	— (loss-making)	—	n/m	−25.60% (below 0%: shrinking)	0.00%	0.00%	Compare
DNA Ginkgo Bioworks Holdings, Inc.	$791.9M	— (loss-making)	— (loss-making)	−48.49% (below 0%: shrinking)	n/m	−16.38% (below 0%: shrinking)	91.47%	(290.47%)	Compare
GERN Geron Corporation	$790.2M	— (loss-making)	— (loss-making)	+17.22% (above 0%: growing)	n/m	+41.82% (above 0%: growing)	83.92%	(21.74%)	Compare
Median of peers	$828.2M	—	—	+17.22%	—	−30.02%	89.92%	(51.68%)

All 614 Biotechnology stocks →

Ardelyx, Inc. (ARDX) key facts

Strength: Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024.
Ardelyx, Inc. (ARDX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ARDX traded at $3.09, a market capitalization of $814.9 million.
Return on equity was −36.2% and debt-to-equity 1.69.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 1.12 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.